Unidad de Dermatología, Hospital de San Jorge de Huesca, and Institute of Health Science of Aragón, Zaragoza, Spain.
Departamento de Biología Molecular, Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Córdoba, Argentina.
J Invest Dermatol. 2014 Sep;134(9):2428-2437. doi: 10.1038/jid.2014.178. Epub 2014 Apr 9.
Photodynamic therapy (PDT) is widely used to treat non-melanoma skin cancer. However, some patients affected with squamous cell carcinoma (SCC) do not respond adequately to PDT with methyl-δ-aminolevulinic acid (MAL-PDT) and the tumors acquire an infiltrative phenotype and became histologically more aggressive, less differentiated, and more fibroblastic. To search for potential factors implicated in SCC resistance to PDT, we have used the SCC-13 cell line (parental) and resistant SCC-13 cells obtained by repeated MAL-PDT treatments (5th and 10th PDT-resistant generations). Xenografts assays in immunodeficient mice showed that the tumors generated by resistant cells were bigger than those induced by parental cells. Comparative genomic hybridization array (aCGH) showed that the three cell types presented amplicons in 3p12.1 CADM2, 7p11.2 EFGR, and 11q13.3 CCND1 genes. The 5th and 10th PDT-resistant cells showed an amplicon in 5q11.2 MAP3K1, which was not present in parental cells. The changes detected by aCGH on CCND1, EFGR, and MAP3K1 were confirmed in extracts of SCC-13 cells by reverse-transcriptase PCR and by western blot, and by immunohistochemistry in human biopsies from persistent tumors after MAL-PDT. Our data suggest that genomic imbalances related to CCND1, EFGR, and particularly MAP3K1 seem to be involved in the development of the resistance of SCC to PDT.
光动力疗法(PDT)被广泛用于治疗非黑素瘤皮肤癌。然而,一些患有鳞状细胞癌(SCC)的患者对甲基-δ-氨基酮戊酸(MAL-PDT)的 PDT 反应不足,肿瘤获得浸润表型,在组织学上变得更具侵袭性、分化程度更低、更成纤维细胞样。为了寻找 SCC 对 PDT 耐药的潜在因素,我们使用了 SCC-13 细胞系(亲本)和通过反复 MAL-PDT 处理(第 5 代和第 10 代 PDT 耐药代)获得的耐药 SCC-13 细胞。免疫缺陷小鼠的异种移植实验表明,由耐药细胞产生的肿瘤比由亲本细胞产生的肿瘤更大。比较基因组杂交阵列(aCGH)显示,三种细胞类型在 3p12.1 CADM2、7p11.2 EFGR 和 11q13.3 CCND1 基因中均存在扩增子。第 5 代和第 10 代 PDT 耐药细胞在 5q11.2 MAP3K1 中显示出扩增子,而亲本细胞中不存在该扩增子。通过 aCGH 检测到的 CCND1、EFGR 和 MAP3K1 变化在 SCC-13 细胞提取物中通过逆转录 PCR 和 Western blot 以及 MAL-PDT 后持续性肿瘤的免疫组织化学得到证实。我们的数据表明,与 CCND1、EFGR 相关的基因组失衡,特别是 MAP3K1,似乎与 SCC 对 PDT 的耐药性发展有关。